drugset / Trial / NCT02115035
A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib
NaSingle-groupOpen-labelTreatment
Summary
The objective is to evaluate the overall response rate of Vermurafenib when administered orally to patients with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2014-07
- Primary completion
- 2017-07
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vemurafenib | Small molecule | 960 mg | Oral |